Peer-reviewed veterinary case report
MicroPulse laser treatment controls glaucoma in dogs
By Sebbag, Lionel et al.·Published in Veterinary ophthalmology·2019·Department of Veterinary Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: MicroPulsetransscleral cyclophotocoagulation in the treatment of canine glaucoma: Preliminary results (12 dogs).
- Species:
- dog
Plain-English summary
A group of 12 dogs aged 2 to 13 years with glaucoma (a condition that increases pressure in the eye) underwent a new laser treatment called MicroPulse transscleral cyclophotocoagulation (MP-TSCPC). Most dogs showed a significant drop in eye pressure within a couple of weeks after the procedure, and about half retained their vision for several months. However, some dogs experienced complications like decreased sensitivity in the cornea and inflammation. Overall, while this treatment can help manage glaucoma in dogs, more research is needed to enhance its long-term effectiveness and minimize side effects.
People also search for: dog glaucoma treatment · MicroPulse laser for dogs · dog eye pressure management
Abstract
OBJECTIVE: To describe the clinical application and effect of MicroPulse™ transscleral cyclophotocoagulation (MP-TSCPC) in dogs with glaucoma. ANIMALS STUDIED: Twelve dogs with primary (n = 8) or secondary (n = 4) glaucoma, aged 2-13 years (mean ± SD, 7.2 ± 3.8 years). PROCEDURES: MP-TSCPC was performed under sedation or general anesthesia. Laser duty cycle was 31.3%, laser power varied from 2000-2800 mW, and each hemisphere was treated for 90-180 seconds. The probe was applied to each quadrant in a "sweeping motion," sparing the 3 and 9 o'clock positions. RESULTS: The number of MP-TSCPC procedures per eye varied from 1 to 3 (1.4 ± 0.7). Intraocular pressure (IOP) was controlled (<25 mm Hg) in 11/12 dogs (92%) within 1-15 days post-operatively. The IOP control at 1 month and the duration between repeated procedures were significantly greater in eyes treated with high energy laser (2800 mW) compared to 2000-2500 mW. Long-term follow-up (315.3 ± 100.7 days) showed controlled IOP in 5/12 (42%) and vision retention in 4/8 (50%) dogs. In unsuccessful cases, loss of IOP control or vision loss occurred within 3-245 days (109.1 ± 93.7 days) and 28-261 days (114 ± 101.6 days), respectively, resulting in a salvage procedure in 6 dogs. Complications were as follows: corneal hypoesthesia (92%), anterior uveitis (67%), post-operative ocular hypertension (50%), neurotrophic corneal ulcer (25%), keratoconjunctivitis sicca (8%), and rubeosis iridis (8%). CONCLUSIONS: MP-TSCPC is a viable tool for managing canine glaucoma, although further studies are required to improve the long-term effect and reduce the complication rate.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30109763/